Please login to the form below

Not currently logged in
Email:
Password:

oritavancin

This page shows the latest oritavancin news and features for those working in and with pharma, biotech and healthcare.

Actavis gets FDA nod for new antibiotic

Actavis gets FDA nod for new antibiotic

dalbavancin) and The Medicine Company's Orbactiv (oritavancin).

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new medicines backed by EMA scientific advisers in the Committee for Medicinal Products for Human

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to Sivextro, the agency also gave a green light this year to Durata Therapeutics' Dalvance (dalbavancin) - recently acquired by Actavis - and The Medicines Company's Orbactiv (oritavancin).

  • Actavis buys infectious disease specialist Durata Actavis buys infectious disease specialist Durata

    Cubicin (daptomycin) and Sivextro (tidezolid) and The Medicine Company's Orbactiv (oritavancin) in the ABSSSI category.

  • FDA approves antibacterial skin drug Orbactiv FDA approves antibacterial skin drug Orbactiv

    US regulator authorises Medicines Company's treatment for ABSSSI. The Food and Drug Administration has approved antibacterial drug Orbactiv (oritavancin) to treat adults with acute bacterial skin and skin structure infections

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    2020. Other drugs in development to treat ABSSSIs include Furiex Pharmaceuticals' avarofloxacin (phase III), Melinta Therapeutics' delafloxacin (phase III) and The Medicines Company's oritavancin (filed for approval in the US).

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics